3.28
0.15 (4.79%)
| Previous Close | 3.13 |
| Open | 3.00 |
| Volume | 14,984 |
| Avg. Volume (3M) | 31,304 |
| Market Cap | 35,314,448 |
| Price / Sales | 0.410 |
| Price / Book | 0.370 |
| 52 Weeks Range | |
| Earnings Date | 26 May 2025 - 30 May 2025 |
| Profit Margin | -67.20% |
| Operating Margin (TTM) | -37.14% |
| Diluted EPS (TTM) | -4.62 |
| Quarterly Revenue Growth (YOY) | 4.10% |
| Total Debt/Equity (MRQ) | 9.01% |
| Current Ratio (MRQ) | 2.92 |
| Operating Cash Flow (TTM) | -92.26 M |
| Levered Free Cash Flow (TTM) | -60.07 M |
| Return on Assets (TTM) | -20.93% |
| Return on Equity (TTM) | -51.38% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Burning Rock Biotech Limited | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| % Held by Insiders | 0.04% |
| % Held by Institutions | 64.35% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Crcm Lp | 31 Dec 2024 | 325,969 |
| Shen Neil Nanpeng | 31 Dec 2024 | 885 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Mar 2025 | Announcement | Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |